| A gene-expression signature as a predictor of survival in breast cancer MJ Van De Vijver, YD He, LJ Van't Veer, H Dai, AAM Hart, DW Voskuil, ... New England Journal of Medicine 347 (25), 1999-2009, 2002 | 7730 | 2002 |
| Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial JA van Dongen, AC Voogd, IS Fentiman, C Legrand, RJ Sylvester, ... Journal of the National Cancer Institute 92 (14), 1143-1150, 2000 | 1675 | 2000 |
| Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer C Schaake-Koning, W Van den Bogaert, O Dalesio, J Festen, ... New England Journal of Medicine 326 (8), 524-530, 1992 | 1610 | 1992 |
| Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the … H Bartelink, F Roelofsen, F Eschwege, P Rougier, JF Bosset, ... Journal of clinical oncology 15 (5), 2040-2049, 1997 | 1506 | 1997 |
| Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost … H Bartelink, JC Horiot, PM Poortmans, H Struikmans, W Van den Bogaert, ... Journal of Clinical Oncology 25 (22), 3259-3265, 2007 | 1322 | 2007 |
| Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation H Bartelink, JC Horiot, P Poortmans, H Struikmans, W Van den Bogaert, ... New England Journal of Medicine 345 (19), 1378-1387, 2001 | 1206 | 2001 |
| Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival HY Chang, DSA Nuyten, JB Sneddon, T Hastie, R Tibshirani, T Sørlie, ... Proceedings of the national academy of sciences 102 (10), 3738-3743, 2005 | 1159 | 2005 |
| Internal mammary and medial supraclavicular irradiation in breast cancer PM Poortmans, S Collette, C Kirkove, E Van Limbergen, V Budach, ... New England Journal of Medicine 373 (4), 317-327, 2015 | 1059 | 2015 |
| Long-term risk of cardiovascular disease in 10-year survivors of breast cancer MJ Hooning, A Botma, BMP Aleman, MHA Baaijens, H Bartelink, ... Journal of the National Cancer Institute 99 (5), 365-375, 2007 | 1026 | 2007 |
| Long-term cause-specific mortality of patients treated for Hodgkin’s lymphoma BMP Aleman, AW van den Belt-Dusebout, WJ Klokman, MB van’t Veer, ... J Clin Oncol 21, 3431-9, 2003 | 855 | 2003 |
| Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas B Kreike, M van Kouwenhove, H Horlings, B Weigelt, H Peterse, ... Breast Cancer Research 9, 1-14, 2007 | 849 | 2007 |
| Late cardiotoxicity after treatment for Hodgkin lymphoma BMP Aleman, AW van den Belt-Dusebout, ML De Bruin, MB van't Veer, ... Blood 109 (5), 1878-1886, 2007 | 844 | 2007 |
| Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized … N Bijker, P Meijnen, JL Peterse, J Bogaerts, I Van Hoorebeeck, J Julien, ... Journal of clinical oncology 24 (21), 3381-3387, 2006 | 784 | 2006 |
| Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853 JP Julien, N Bijker, IS Fentiman, JL Peterse, V Delledonne, P Rouanet, ... The Lancet 355 (9203), 528-533, 2000 | 771 | 2000 |
| Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large … AC Voogd, M Nielsen, JL Peterse, M Blichert-Toft, H Bartelink, ... Journal of clinical oncology 19 (6), 1688-1697, 2001 | 723 | 2001 |
| Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial H Bartelink, P Maingon, P Poortmans, C Weltens, A Fourquet, J Jager, ... The lancet oncology 16 (1), 47-56, 2015 | 681 | 2015 |
| Late effects toxicity scoring: the SOMA scale JJ Pavy, J Denekamp, J Letschert, B Littbrand, F Mornex, J Bernier, ... Radiotherapy and Oncology 35 (1), 11-15, 1995 | 681 | 1995 |
| Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial S Litière, G Werutsky, IS Fentiman, E Rutgers, MR Christiaens, ... The lancet oncology 13 (4), 412-419, 2012 | 675 | 2012 |
| Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. JA Van Dongen, H Bartelink, IS Fentiman, T Lerut, F Mignolet, G Olthuis, ... Journal of the National Cancer Institute. Monographs, 15-18, 1992 | 674 | 1992 |
| Prognostic factors of neck node metastasis GB Snow, AA Annyas, EA Slooten, H Bartelink, AAM Hart Clinical Otolaryngology & Allied Sciences 7 (3), 185-192, 1982 | 620 | 1982 |
